Zobrazeno 1 - 10
of 194
pro vyhledávání: '"TLR9 agonist"'
Publikováno v:
Advanced Science, Vol 11, Iss 41, Pp n/a-n/a (2024)
Abstract The effectiveness of Toll‐like 9 agonists (CpG) as an adjuvant for tumor immunotherapy is restricted due to their insufficient ability to activate anti‐tumor immunity. To address that, the common nutrient metal ions are explored (Mn2+, C
Externí odkaz:
https://doaj.org/article/5bf23fd39bbf4256ae17f8aa30b5f030
Autor:
Anna R. Mahr, Maia M. C. Bennett-Boehm, Frederik H. Rothemejer, Isabelle S. Weber, Alexander K. Regan, Josh Q. Franzen, Cami R. Bisson, Angela N. Truong, Rikke Olesen, Mariane H. Schleimann, Claudia M. Rauter, Audrey L. Smith, Dalia El-Gamal, Ole S. Søgaard, Martin Tolstrup, Paul W. Denton
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract There are two known mechanisms by which natural killer (NK) cells recognize and kill diseased targets: (i) direct killing and (ii) antibody-dependent cell-mediated cytotoxicity (ADCC). We investigated an indirect NK cell activation strategy
Externí odkaz:
https://doaj.org/article/85906b314a2a4acaaca1f37e36865354
Autor:
Zhichen Sun, Yanhong Chu, Jie Xiao, Yueling Yang, Fanyan Meng, Xinyue Wang, Yanbing Dong, Junmeng Zhu, Yirong Wu, Lanqun Qin, Yaohua Ke, Baorui Liu, Qin Liu
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background In situ tumor vaccine has been gradually becoming a hot research field for its advantage of achieving personalized tumor therapy without prior antigen identification. Various in situ tumor vaccine regimens have been reported to ex
Externí odkaz:
https://doaj.org/article/95f2cfb3cf294e399045905095faafe3
Autor:
Sare Hajiabadi, Soodeh Alidadi, Mohammad Mehdi Ghahramani Senoo, Zohreh Montakhab Farahi, Hamid Reza Farzin, Alireza Haghparast
Publikováno v:
The Iranian Journal of Veterinary Science and Technology, Vol 15, Iss 2, Pp 29-37 (2023)
Cancer immunotherapy emerged as a novel therapeutic approach to destroy tumor cells, and it has grown toward clinical transition following successful fundamental research and clinical trials. Immunotherapy by efficacious adjuvants is critical for inc
Externí odkaz:
https://doaj.org/article/59db2281ba304addb2adb9d6a8547a0c
Publikováno v:
Vaccines, Vol 12, Iss 6, p 649 (2024)
Oligodeoxynucleotides (ODNs) containing unmethylated cytosine–phosphate–guanosine (CpG) motifs are readily recognized by Toll-like receptor 9 on immune cells, trigger an immunomodulatory cascade, induce a Th1 -biased immune milieu, and have great
Externí odkaz:
https://doaj.org/article/8186dd51597a4f429d894368e7678197
Publikováno v:
Emerging Microbes and Infections, Vol 12, Iss 2 (2023)
Antigen sparing is an important strategy for pandemic vaccine development because of the limitation of worldwide vaccine production during disease outbreaks. However, several clinical studies have demonstrated that the current aluminum (Alum)-adjuvan
Externí odkaz:
https://doaj.org/article/390547a045fc40a8a695635f606df02d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marcelo V. Negrao, MD, Vassiliki A. Papadimitrakopoulou, MD, Andrew C. Price, MD, PhD, Alda L. Tam, MD, MBA, Muhammad Furqan, MD, Sandeep T. Laroia, MD, Erminia Massarelli, MS, MD, PhD, Jose Pacheco, MD, John V. Heymach, MD, PhD, Anne S. Tsao, MD, Gary V. Walker, MD, Lalit Vora, MD, David Mauro, MD, PhD, Heather Kelley, MA, James E. Wooldridge, MD, Arthur M. Krieg, MD, Jiaxin Niu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100423- (2023)
Introduction: Vidutolimod, a CpG-A TLR9 agonist, was investigated in a phase 1b study (CMP-001-003; ClinicalTrials.gov, NCT03438318) in combination with atezolizumab with and without radiation therapy (RT) in patients with advanced NSCLC. Methods: Pa
Externí odkaz:
https://doaj.org/article/375520c714da4dd0a0459208063f6fc7